9EGE image
Deposition Date 2024-11-21
Release Date 2025-04-02
Last Version Date 2025-06-11
Entry Detail
PDB ID:
9EGE
Title:
BSEP Apo Structure in GDN
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.80 Å
Aggregation State:
PARTICLE
Reconstruction Method:
SINGLE PARTICLE
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Bile salt export pump
Gene (Uniprot):ABCB11
Chain IDs:A
Chain Length:1321
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
A structural and mechanistic model for BSEP dysfunction in PFIC2 cholestatic disease.
Commun Biol 8 531 531 (2025)
PMID: 40195555 DOI: 10.1038/s42003-025-07908-0

Abstact

BSEP (ABCB11) transports bile salts across the canalicular membrane of hepatocytes, where they are incorporated into bile. Biallelic mutations in BSEP can cause Progressive Familial Intrahepatic Cholestasis Type 2 (PFIC2), a rare pediatric disease characterized by hepatic bile acid accumulation leading to hepatotoxicity and, ultimately, liver failure. The most frequently occurring PFIC2 disease-causing mutations are missense mutations, which often display a phenotype with decreased protein expression and impaired maturation and trafficking to the canalicular membrane. To characterize the mutational effects on protein thermodynamic stability, we carried out biophysical characterization of 13 distinct PFIC2-associated variants using in-cell thermal shift (CETSA) measurements. These experiments reveal a cluster of residues localized to the NBD2-ICL2 interface, which exhibit severe destabilization relative to wild-type BSEP. A high-resolution (2.8 Å) cryo-EM structure provides a framework for rationalizing the CETSA results, revealing a novel, NBD2-localized mechanism through which the most severe missense patient mutations drive cholestatic disease. These findings suggest potential strategies for identifying mechanism-based small molecule correctors to address BSEP trafficking defects and advance novel therapies for PFIC2 and other cholestatic diseases.

Legend

Protein

Chemical

Disease

Primary Citation of related structures